BofA warns Fed risks policy mistake with early rate cuts
VANCOUVER - Clearmind Medicine Inc. (Nasdaq:CMND) announced Wednesday it has filed a new international patent application under the Patent Cooperation Treaty for a combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
The patent application covers the company’s combination of MEAI (5-methoxy-2-aminoindane and N-Acylethanolamines) and Palmitoylethanolamide (PEA), developed in collaboration with SciSparc Ltd. (Nasdaq:SPRC).
According to the World Health Organization data cited in the press release, obesity affects over 890 million people globally, while non-alcoholic fatty liver disease impacts more than 30% of the global adult population.
"Our goal is to bring meaningful innovation to areas with high unmet medical need," said Dr. Adi Zuloff-Shani, CEO of Clearmind, in the company statement.
The clinical-stage biotech company, which focuses on developing psychedelic-derived therapeutics, currently holds 31 granted patents across 19 patent families, according to the press release.
Clearmind shares are listed on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange as "CWY0."
The company claims the combination therapy could potentially offer a new treatment option for these widespread health conditions, though the patent application is still pending approval.
In other recent news, SciSparc Ltd. announced it will implement a one-for-21 reverse share split effective July 3, 2025. This move will reduce its outstanding ordinary shares from 11,225,751 to approximately 534,600. Additionally, SciSparc has secured a new Japanese divisional patent for a pharmaceutical combination aimed at improving pain and fever treatment. The patent covers a combination of paracetamol and palmitoylethanolamide (PEA), which may enhance relief with lower doses and reduced side effects. Furthermore, SciSparc has scheduled its Annual General Meeting of Shareholders for June 25, 2025. Shareholders on record as of May 27, 2025, will be eligible to vote at the meeting. The meeting will address standard corporate matters as outlined in the company’s recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.